Anti-Obesity Drugs Market Report and Forecast 2025-2034

The anti-obesity drugs market was valued at USD 3.20 Billion in 2024, driven by rising prevalence of obesity across the 8 major markets. The market is expected to grow at a CAGR of 43.72% during the forecast period of 2025-2034, with the values likely to reach USD 120.32 Billion by 2034.

Anti-Obesity Drugs Market Overview

Anti-obesity drugs target different aspects of weight management such as appetite suppression, fat absorption, and metabolic enhancement. There are several anti-obesity drugs approved by the United States Food and Drug Administration (FDA) for long-term use, including Bupropion-naltrexone (Contrave), Liraglutide (Saxenda), Orlistat (Xenical, Alli), Phentermine-topiramate (Qsymia), and Semaglutide (Wegovy), among others. Some weight loss medications like semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound) can help in reducing body weight by 20%.

The anti-obesity drugs market growth is driven by the rising prevalence of obesity worldwide, increasing awareness about the health risks associated with obesity, and growing partnerships in obesity-related research. For instance, in February 2024, Obesity Canada partnered with My Viva Inc., in order to support people living with obesity. “My Viva Plan” created by My Viva is the lifestyle management tool useful for creating personalized fitness planning. Moreover, to raise the awareness among the individuals, International Obesity Collaborative (IOC), a global initiative aimed at addressing the obesity on international scale was also formed. The IOC comprised of 12 international organizations including the obesity medicine association. Furthermore, the surge in drug approvals by health regulatory agencies and innovation in drug development are some of the factors that are expected to positively influence the market landscape.

Anti-Obesity Drugs Market Growth Drivers

Rising Prevalence of Obesity to Foster the Market Landscape Significantly

The market is driven by rising prevalence of obesity which makes an individual prone to various health complications such as diabetes, cardiovascular diseases, and certain cancers. According to the World Health Organization (WHO), in 2022, around 2.5 billion adults (18 years or older) were overweight, out of which around 890 million adults were living with obesity. This equates to about 43% of the adults being overweight which shows an increase from the 1990, when 25% of adults aged 18 years and above were overweight. In addition, as per the latest World Obesity Atlas 2023, it is expected that the number of individuals falling in the overweight and obesity category will reach 4 billion by 2035. This indicates that every 1 in 5 women and 1 in 7 men, will be living with obesity by 2030.

Increased Strategic Merger and Initiatives to Meet Rising Anti-Obesity Drugs Market Demand

One of the significant market trends is the rise in strategic merger and acquisition initiatives taken by the key market players to expand production capacities and support the development of novel drug pipelines. Recently, in January 2024, Roche completed the acquisition of Carmot Therapeutics Inc. dedicated in developing the therapeutics for the people living with metabolic diseases including obesity and diabetes. Further, rising investments aimed at introducing safer and more efficient anti-obesity drugs in the market are also anticipated to accelerate market growth. In January 2024, Adipo Therapeutics closed a USD 1.9 million seed financing gap to advance the treatment of Type 2 diabetes and obesity.

Anti-Obesity Drugs Market Trends

The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:

Increased Focus on Combination Therapies

There is a growing interest in combination therapies that target multiple pathways to induce weight loss. Such combinations can offer better efficacy as compared to conventional monotherapies.

Heightened Patient Awareness

There is an increased awareness and acceptance of obesity as a chronic disease requiring medical intervention, rather than just lifestyle changes. This shift is contributing to the rising anti-obesity drugs market demand.

Regulatory Support

Regulatory agencies are providing transparent guidelines and support for the development and approval of anti-obesity drugs. This includes fast-track designations and approvals for drugs that exhibit significant benefits in clinical trials.

Increased Use of GLP-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for diabetes treatment, are increasingly preferred for obesity management due to their ability to induce weight loss.

Anti-Obesity Drugs Market Segmentation

"Global Anti-Obesity Drugs Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:

Breakup by Drug Type

• Semaglutide
• Phentermine/Topiramate
• Naltrexone/Bupropion
• Liraglutide
• Gelesis 100
• Orlistat
• Phentermine
• Methamphetamine
• Tirzepatide
• Others

Breakup by Drug Class

• Amphetamine
• GLP-1 Receptor Agonist
• Lipase Inhibitor
• Others

Breakup by Mechanism of Action

• Centrally Acting Drugs
• Peripherally Acting Drugs

Breakup by Prescription Type

• Prescription Drugs
• Over The Counter Drugs

Breakup by Distribution Channel

• Hospital Pharmacies
• Drug Store & Retail Pharmacies
• Online Pharmacies

Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

Anti-Obesity Drugs Market Share

Market Segmentation Based on Product Type is Anticipated to Witness Substantial Growth

By drugs, the market is segmented into Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, and Tirzepatide. Each anti-obesity drug works on distinct mechanisms and shows different effects on weight management. Among the different anti-obesity drugs, the two anti-obesity drugs that have been approved for long-term usage are sibutramine and orlistat. However, they can even cause minor side-effects such as flatulence and diarrhea.

Anti-Obesity Drugs Market Analysis by Region

Based on region, United States is the market is witnessing significant growth which can attributed to an advanced healthcare system offering access to various anti-obesity drugs to the huge patient population. With 78% of adults in the United States estimated to be overweight or obese by 2030, the rising prevalence of obesity in the region is poised to propel the market growth in the coming years. In addition, the increased funding, and investments to support the development of novel weight loss drugs is expected to augment the anti-obesity drugs market demand.

Europe also holds a high market value, owing to the presence of leading market players in the region. Moreover, the dominance of the regional market is a result of the rising adoption of obesity treatment solutions and growing investments in obesity research and drug development. India is projected to witness substantial growth. It can be accredited to changing lifestyle of the people that can result in obesity.

Leading Players in the Anti-Obesity Drugs Market

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Novo Nordisk A/S

Established over 100 years ago, Novo Nordisk is a Danish pharmaceutical company that boasts a well-established anti-obesity drugs portfolio, including Wegovy and amycretin. Wegovy is a prescription based injectable while amycretin is an oral pill that works by stimulating gut hormones and controls blood sugar levels along with appetite.

Eli Lilly and Company

United States based Eli Lilly and Company spans across 18 countries. It has 2 major anti-obesity drugs including Mounjaro and Zepbound. Zepbound™ (tirzepatide) intended for chronic weight management received FDA approval in November 2023. The company has also initiated phase three clinical trials for a novel oral weight-loss drug called orforglipron in India.

Other major market players include Rhythm Pharmaceuticals, KVK Tech Inc., Currax Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Vivus LLC, Gelesis Holding Inc., GlaxoSmithKline PLC, Pfizer Inc., and Boehringer Ingelheim International GmbH.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in the Anti-Obesity Drugs Market Report

• What was the anti-obesity drugs market value in 2023?
• What is the anti-obesity drugs market forecast outlook for 2025-2034?
• What are the regional markets covered in the report?
• What is market segmentation based on drug type?
• Who are the major distribution channels in the market?
• What are the major factors aiding the anti-obesity drugs market demand?
• How has the anti-obesity drugs market performed so far and how is it anticipated to perform in the coming years?
• What are the major trends influencing the market?
• What is the market breakup based on drug class?
• What is the market segmentation prescription type?
• What are the market's major drivers, opportunities, and restraints?
• Which country is expected to experience expedited growth during the forecast period?
• How does the prevalence of obesity affect the market landscape?
• Which drug type will dominate the market share?
• How does the changing lifestyle of the people will impact the market size?
• Which distribution channel will experience the highest demand in the market segment?
• Based on the mechanism of action, which segment will dominate the market?
• Which prescription type will dominate the market?
• Who are the key players involved in the anti-obesity drugs market?
• What is patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.